{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:42:15Z","timestamp":1792208535988,"version":"4.4.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy (nCT) for esophageal and esophagogastric junction (EGJ) adenocarcinoma is associated with better survival but worse pathological complete response (pCR) rate as compared with neoadjuvant chemoradiotherapy (nCRT). The aim of the present study is to compare long-term outcomes in patients with esophageal or EGJ adenocarcinoma and pCR after nCT or nCRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>A systematic review of the literature in PubMed, Embase and web sources was performed up to November 2025. Studies comparing nCT and nCRT in patients with esophageal or EGJ adenocarcinoma and pCR were identified. An individual patient-data (IPD) meta-analysis was performed for overall survival (OS) and disease-free survival (DFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 1454 patients from six different studies were included (374 in nCT group and 1080 in nCRT group). 1-, 3-, and 5-year OS was superior in the nCT group as compared with nCRT group, being 95.4% versus 87.8%, 81.5% versus 64.8% and 73.8% versus 56%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Analogously, superior DFS was observed for the nCT group at one, three and 5 years (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). In the one-stage meta-analysis nCT was associated with decreased risk of death (HR = 0.49,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and recurrence (HR = 0.24,\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The present study showed better long-term outcomes in patients with pCR after nCT when compared with nCRT, highlighting the better systemic disease control offered by the first. This consideration suggests that pCR cannot be considered as a prognostic surrogate per se but the integration of this concept with the type of preoperative strategy is crucial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20296-x","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:14:59Z","timestamp":1785165299000},"page":"10301-10311","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond Pathological Complete Response: Long-term Outcomes in Esophageal and Esophagogastric Junction Adenocarcinoma After Multimodal Therapy\u2014A Systematic Review and Individual Patient-Data Meta-Analysis"],"prefix":"10.1245","volume":"33","author":[{"given":"Luca","family":"Risi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Enrico","family":"Meneghesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Basato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Castoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Maria","family":"Garbarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"8","key":"20296_CR1","first-page":"656","volume":"21","author":"Y Teng","year":"2024","unstructured":"Teng Y, Xia C, Cao M, et al. Esophageal cancer global burden profiles, trends, and contributors. Cancer Biol Med. 2024;21(8):656\u201366.","journal-title":"Cancer Biol Med."},{"issue":"2","key":"20296_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.14740\/wjon1254","volume":"11","author":"EO Then","year":"2020","unstructured":"Then EO, Lopez M, Saleem S, et al. Esophageal cancer: an updated surveillance epidemiology and end results database analysis. World J Oncol. 2020;11(2):55\u201364.","journal-title":"World J Oncol."},{"issue":"1","key":"20296_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/jgo-22-729","volume":"14","author":"SH Tella","year":"2023","unstructured":"Tella SH, Mara K, Chakrabarti S, Jin Z, Mahipal A. A glimpse into the future of esophageal carcinoma in the United States: predicting the future incidence until 2040 based on the current epidemiological data. J Gastrointest Oncol. 2023;14(1):1\u201310.","journal-title":"J Gastrointest Oncol."},{"issue":"5","key":"20296_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41416-021-01485-9","volume":"126","author":"JC Bolger","year":"2022","unstructured":"Bolger JC, Donohoe CL, Lowery M, Reynolds JV. Advances in the curative management of oesophageal cancer. Br J Cancer. 2022;126(5):706\u201317.","journal-title":"Br J Cancer."},{"key":"20296_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemo- therapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med."},{"key":"20296_CR6","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","volume":"27","author":"WH Allum","year":"2009","unstructured":"Allum WH, Stenning SP, Bancewicz J, et al. Long-term results of a randomised trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062\u20137.","journal-title":"J Clin Oncol."},{"key":"20296_CR7","doi-asserted-by":"crossref","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. (2012). 31;366(22):2074-84.","DOI":"10.1056\/NEJMoa1112088"},{"issue":"10184","key":"20296_CR8","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357.","journal-title":"Lancet."},{"issue":"10","key":"20296_CR9","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannov\u00e1","year":"2022","unstructured":"Obermannov\u00e1 R, Alsina M, Cervantes A, et al. ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992\u20131004.","journal-title":"Ann Oncol."},{"issue":"11","key":"20296_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S2468-1253(23)00243-1","volume":"8","author":"JV Reynolds","year":"2023","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B, et al. Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(11):1015\u201327.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"4","key":"20296_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa2409408","volume":"392","author":"J Hoeppner","year":"2025","unstructured":"Hoeppner J, Brunner T, Schmoor C, et al. Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer. N Engl J Med. 2025;392(4):323\u201335.","journal-title":"N Engl J Med."},{"issue":"2","key":"20296_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104134","volume":"10","author":"RL Obermannov\u00e1","year":"2025","unstructured":"Obermannov\u00e1 RL, Leong T. ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma. ESMO Open. 2025;10(2):104134.","journal-title":"ESMO Open."},{"key":"20296_CR13","doi-asserted-by":"crossref","unstructured":"Chidambaram S, Sounderajah V, Maynard N, Markar SR. Evaluation of post-operative surveillance strategies for esophageal and gastric cancers: a systematic review and meta-analysis. Dis Esophagus. (2022). 35(12):doac034.","DOI":"10.1093\/dote\/doac034"},{"key":"20296_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.103067","volume":"80","author":"H Van Laarhoven","year":"2025","unstructured":"Van Laarhoven H, Verhoeven R, van Berge Henegouwen M, et al. Real-world outcomes of the CROSS regimen in patients with resectable esophageal or gastro-esophageal junction adenocarcinoma: a nationwide cohort study in the Netherlands. EClinicalMedicine. 2025;80:103067.","journal-title":"EClinicalMedicine."},{"key":"20296_CR15","doi-asserted-by":"crossref","unstructured":"Oesophago-Gastric Anastomotic Audit (OGAA) Collaborative. Postoperative and pathological outcomes of CROSS and FLOT as neoadjuvant therapy for esophageal and junctional adenocarcinoma: an international cohort study from the Oesophagogastric Anastomosis Audit (OGAA). Ann Surg. (2023). 277(5):e1026-e1034.","DOI":"10.1097\/SLA.0000000000005394"},{"issue":"5","key":"20296_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/SLA.0000000000005619","volume":"276","author":"J Cools-Lartigue","year":"2022","unstructured":"Cools-Lartigue J, Markar S, Mueller C, et al. An International cohort study of prognosis associated with pathologically complete response following neoadjuvant chemotherapy versus chemoradiotherapy of surgical treated esophageal adenocarcinoma. Ann Surg. 2022;276(5):799\u2013805.","journal-title":"Ann Surg."},{"issue":"1","key":"20296_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00423-023-03100-2","volume":"408","author":"J Hipp","year":"2023","unstructured":"Hipp J, Kuvendjiska J, Hillebrecht HC, et al. Oncological recurrence following pathological complete response after neoadjuvant treatment in patients with esophageal cancer - a retrospective cohort study. Langenbecks Arch Surg. 2023;408(1):363.","journal-title":"Langenbecks Arch Surg."},{"key":"20296_CR18","doi-asserted-by":"crossref","unstructured":"Capovilla G, Pierobon ES, Moletta L, et al. Prognostic value of tumor regression grade after chemotherapy versus chemoradiotherapy in patients undergoing neoadjuvant treatment for locally advanced esophageal adenocarcinoma. Ann Surg Oncol. (2025). Epub ahead of print.","DOI":"10.1245\/s10434-025-17264-2"},{"issue":"1","key":"20296_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev."},{"issue":"12","key":"20296_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1471-2288-12-9","volume":"1","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;1(12):9.","journal-title":"BMC Med Res Methodol."},{"issue":"8","key":"20296_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"7","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;7(8):16.","journal-title":"Trials."},{"issue":"4","key":"20296_CR22","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","volume":"17","author":"Y Wei","year":"2017","unstructured":"Wei Y, Royston P. Reconstructing time-to-event data from published Kaplan-Meier curves. Stata J. 2017;17(4):786\u2013802.","journal-title":"Stata J."},{"issue":"2","key":"20296_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/jrsm.1384","volume":"11","author":"VMT de Jong","year":"2020","unstructured":"de Jong VMT, Moons KGM, Riley RD, et al. Individual participant data meta-analysis of intervention studies with time-to-event outcomes: a review of the methodology and an applied example. Res Synth Methods. 2020;11(2):148\u201368.","journal-title":"Res Synth Methods."},{"issue":"5","key":"20296_CR24","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/sim.7141","volume":"36","author":"DL Burke","year":"2017","unstructured":"Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. 2017;36(5):855\u201375.","journal-title":"Stat Med."},{"key":"20296_CR25","doi-asserted-by":"publisher","unstructured":"Lueza B, Rotolo F, Bonastre J, Pignon JP, Michiels S. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. BMC Med Res Methodol. 2016;16:37. Published 2016 Mar 29. https:\/\/doi.org\/10.1186\/s12874-016-0137-z","DOI":"10.1186\/s12874-016-0137-z"},{"issue":"19","key":"20296_CR26","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/sim.4274","volume":"30","author":"P Royston","year":"2011","unstructured":"Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30(19):2409\u201321. https:\/\/doi.org\/10.1002\/sim.4274.","journal-title":"Stat Med."},{"key":"20296_CR27","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000."},{"issue":"11","key":"20296_CR28","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/s41416-023-02232-y","volume":"128","author":"AI Damanakis","year":"2023","unstructured":"Damanakis AI, Gebauer F, Stapper A, et al. Combined regression score predicts outcome after neoadjuvant treatment of oesophageal cancer. Br J Cancer. 2023;128(11):2025\u201335.","journal-title":"Br J Cancer."},{"issue":"1","key":"20296_CR29","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10120-019-00980-6","volume":"23","author":"M Xiang","year":"2020","unstructured":"Xiang M, Chang DT, Heestand GM, Pollom EL. Survival after neoadjuvant approaches to gastroesophageal junction cancer. Gastric Cancer. 2020;23(1):175\u201383.","journal-title":"Gastric Cancer."},{"issue":"1","key":"20296_CR30","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1245\/s10434-025-18140-9","volume":"33","author":"R Shridhar","year":"2026","unstructured":"Shridhar R, Huston J, Meredith K. Outcomes of neoadjuvant chemotherapy versus chemoradiation for esophageal adenocarcinoma: a national cancer database analysis. Ann Surg Oncol. 2026;33(1):482\u201391.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"20296_CR31","first-page":"2680","volume":"73","author":"AM Mandard","year":"1994","unstructured":"Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations Cancer. 1994;73(11):2680\u20136.","journal-title":"Clinicopathologic correlations. Cancer."},{"issue":"21","key":"20296_CR32","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1002\/cncr.30953","volume":"123","author":"M Blum Murphy","year":"2017","unstructured":"Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017;123(21):4106\u201313.","journal-title":"Cancer."},{"key":"20296_CR33","doi-asserted-by":"crossref","unstructured":"Hipp J, Kuvendjiska J, Hillebrecht HC et al. Pathological complete response in multimodal treatment of esophageal cancer: a retrospective cohort study. Dis Esophagus. (2023). 36(7):doac095.","DOI":"10.1093\/dote\/doac095"},{"issue":"8","key":"20296_CR34","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ejso.2017.06.003","volume":"43","author":"F Favi","year":"2017","unstructured":"Favi F, Bollschweiler E, Berlth F, et al. Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? A propensity score-matched study. Eur J Surg Oncol. 2017;43(8):1572\u201380.","journal-title":"Eur J Surg Oncol."},{"issue":"4","key":"20296_CR35","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s13304-023-01497-5","volume":"75","author":"PM Lombardi","year":"2023","unstructured":"Lombardi PM, Pansa A, Basato S, et al. Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution. Updates Surg. 2023;75(4):921\u201330.","journal-title":"Updates Surg."},{"issue":"1","key":"20296_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000531536","volume":"10","author":"A Shahnam","year":"2023","unstructured":"Shahnam A, Nindra U, McNamee N, et al. Real-world outcomes of FLOT versus CROSS regimens for patients with oesophagogastric cancers. Gastrointest Tumors. 2023;10(1):19\u201328.","journal-title":"Gastrointest Tumors."},{"issue":"3","key":"20296_CR37","doi-asserted-by":"publisher","first-page":"326","DOI":"10.29271\/jcpsp.2021.03.326","volume":"31","author":"I Karadag","year":"2021","unstructured":"Karadag I, Karakaya S, Ates O, Cakmak Oksuzoglu OB. CROSS or FLOT in distal esophageal and gastroesophageal cancer. J Coll Physicians Surg Pak. 2021;31(3):326\u20139.","journal-title":"J Coll Physicians Surg Pak."},{"issue":"4","key":"20296_CR38","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/CCO.0000000000000751","volume":"33","author":"PH Pucher","year":"2021","unstructured":"Pucher PH, Wijnhoven BPL, Underwood TJ, Reynolds JV, Davies AR. Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon. Curr Opin Oncol. 2021;33(4):353\u201361.","journal-title":"Curr Opin Oncol."},{"issue":"1","key":"20296_CR39","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1186\/s12885-020-07388-x","volume":"20","author":"S Lorenzen","year":"2020","unstructured":"Lorenzen S, Biederst\u00e4dt A, Ronellenfitsch U, et al. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer. 2020;20(1):886.","journal-title":"BMC Cancer."},{"issue":"3","key":"20296_CR40","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217\u201330.","journal-title":"N Engl J Med."},{"issue":"4","key":"20296_CR41","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen S, G\u00f6tze TO, Thuss-Patience P, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III DANTE\/IKF-s633 trial. J Clin Oncol. 2024;42(4):410\u201320.","journal-title":"J Clin Oncol."},{"issue":"38","key":"20296_CR42","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1200\/JCO.2020.38.15_suppl.4502","volume":"25","author":"RD Hofheinz","year":"2020","unstructured":"Hofheinz RD, Haag GM, Ettrichet TJ, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol. 2020;25(38):4502.","journal-title":"J Clin Oncol"},{"issue":"32","key":"20296_CR43","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1200\/JCO.22.00380","volume":"40","author":"RD Hofheinz","year":"2022","unstructured":"Hofheinz RD, Merx K, Haag GM, et al. FLOT versus FLOT\/trastuzumab\/pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA Study Group. J Clin Oncol. 2022;40(32):3750\u201361.","journal-title":"J Clin Oncol."},{"issue":"12","key":"20296_CR44","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1038\/s41591-025-03979-y","volume":"31","author":"A Stein","year":"2025","unstructured":"Stein A, Goekkurt E, Al-Batran SE, et al. Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial. Nat Med. 2025;31(12):4197\u2013204.","journal-title":"Nat Med."},{"issue":"3","key":"20296_CR45","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jtcvs.2018.09.136","volume":"157","author":"A Barbetta","year":"2019","unstructured":"Barbetta A, Sihag S, Nobel T, et al. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery. J Thorac Cardiovasc Surg. 2019;157(3):1249-1259.e5.","journal-title":"J Thorac Cardiovasc Surg."},{"issue":"1","key":"20296_CR46","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/nyas.14462","volume":"1482","author":"X Zhang","year":"2020","unstructured":"Zhang X, Jain D. Updates in staging and pathologic evaluation of esophageal carcinoma following neoadjuvant therapy. Ann N Y Acad Sci. 2020;1482(1):163\u201376.","journal-title":"Ann N Y Acad Sci."},{"issue":"18","key":"20296_CR47","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.3390\/cancers14184498","volume":"14","author":"SJM Hoefnagel","year":"2022","unstructured":"Hoefnagel SJM, Koemans WJ, Khan HN, et al. Identification of novel molecular subgroups in esophageal adenocarcinoma to predict response to neo-adjuvant therapies. Cancers (Basel). 2022;14(18):4498.","journal-title":"Cancers (Basel)."},{"issue":"2","key":"20296_CR48","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13304-022-01379-2","volume":"75","author":"VM Piva","year":"2023","unstructured":"Piva VM, De Grandis MC, Zuin IS, et al. ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma. Updates Surg. 2023;75(2):305\u201312.","journal-title":"Updates Surg."},{"issue":"3","key":"20296_CR49","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology. 2022;163(3):649-658.e2.","journal-title":"Gastroenterology."},{"key":"20296_CR50","doi-asserted-by":"crossref","unstructured":"Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: orient to occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol. (2009). 24(5):729-35.","DOI":"10.1111\/j.1440-1746.2009.05824.x"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20296-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20296-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20296-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:24:05Z","timestamp":1792207445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20296-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["20296"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20296-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"23 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no disclosure.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}